112 related articles for article (PubMed ID: 25174276)
1. Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
[TBL] [Abstract][Full Text] [Related]
2. The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study.
Zauderer MG; Martin A; Egger J; Rizvi H; Offin M; Rimner A; Adusumilli PS; Rusch VW; Kris MG; Sauter JL; Ladanyi M; Shen R
Lancet Digit Health; 2021 Sep; 3(9):e565-e576. PubMed ID: 34332931
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.
Usami N; Fukui T; Kondo M; Taniguchi T; Yokoyama T; Mori S; Yokoi K; Horio Y; Shimokata K; Sekido Y; Hida T
Cancer Sci; 2006 May; 97(5):387-94. PubMed ID: 16630136
[TBL] [Abstract][Full Text] [Related]
4. [Research progress on pathogenesis of malignant mesothelioma].
Mei W; Zhang YP; Yang SJ
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2024 Mar; 42(3):232-240. PubMed ID: 38538248
[TBL] [Abstract][Full Text] [Related]
5. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay.
Schwaederle M; Husain H; Fanta PT; Piccioni DE; Kesari S; Schwab RB; Banks KC; Lanman RB; Talasaz A; Parker BA; Kurzrock R
Oncotarget; 2016 Mar; 7(9):9707-17. PubMed ID: 26848768
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations in neuroendocrine cancers of the ovary.
Yaghmour G; Prouet P; Wiedower E; Jamy OH; Feldman R; Chandler JC; Pandey M; Martin MG
J Ovarian Res; 2016 Aug; 9(1):52. PubMed ID: 27566252
[TBL] [Abstract][Full Text] [Related]
7. Second generation sequencing of the mesothelioma tumor genome.
Bueno R; De Rienzo A; Dong L; Gordon GJ; Hercus CF; Richards WG; Jensen RV; Anwar A; Maulik G; Chirieac LR; Ho KF; Taillon BE; Turcotte CL; Hercus RG; Gullans SR; Sugarbaker DJ
PLoS One; 2010 May; 5(5):e10612. PubMed ID: 20485525
[TBL] [Abstract][Full Text] [Related]
8. Tongue carcinoma infrequently harbor common actionable genetic alterations.
Tan DS; Wang W; Leong HS; Sew PH; Lau DP; Chong FT; Krisna SS; Lim TK; Iyer NG
BMC Cancer; 2014 Sep; 14():679. PubMed ID: 25234657
[TBL] [Abstract][Full Text] [Related]
9. Molecular alterations and potential actionable mutations in peritoneal mesothelioma: a scoping review of high-throughput sequencing studies.
Dietz MV; van Kooten JP; Paats MS; Aerts JGVJ; Verhoef C; Madsen EVE; Dubbink HJ; von der Thüsen JH
ESMO Open; 2023 Aug; 8(4):101600. PubMed ID: 37453150
[TBL] [Abstract][Full Text] [Related]
10. Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.
Hou H; Liu D; Zhang C; Jiang Y; Lu G; Zhou N; Yang X; Zhang X; Li Z; Zhu H; Qian Z; Zhang X
Oncotarget; 2017 Dec; 8(62):105072-105080. PubMed ID: 29285234
[TBL] [Abstract][Full Text] [Related]
11. Genomic profiling of tissue and blood predicts survival outcomes in patients with resected pleural mesothelioma.
de Miguel-Perez D; Pickering EM; Malapelle U; Grier W; Pepe F; Pisapia P; Russo G; Pinto JA; Russo A; Troncone G; Culligan MJ; Scilla KA; Mehra R; Mohindra P; Arrieta O; Cardona AF; Del Re M; Sachdeva A; Hirsch FR; Wolf A; Friedberg JS; Rolfo C
Eur J Cancer; 2024 Jan; 196():113457. PubMed ID: 38008032
[TBL] [Abstract][Full Text] [Related]
12. Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma.
Walker BA; Boyle EM; Wardell CP; Murison A; Begum DB; Dahir NM; Proszek PZ; Johnson DC; Kaiser MF; Melchor L; Aronson LI; Scales M; Pawlyn C; Mirabella F; Jones JR; Brioli A; Mikulasova A; Cairns DA; Gregory WM; Quartilho A; Drayson MT; Russell N; Cook G; Jackson GH; Leleu X; Davies FE; Morgan GJ
J Clin Oncol; 2015 Nov; 33(33):3911-20. PubMed ID: 26282654
[TBL] [Abstract][Full Text] [Related]
13. Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment.
Zhang M; Luo JL; Sun Q; Harber J; Dawson AG; Nakas A; Busacca S; Sharkey AJ; Waller D; Sheaff MT; Richards C; Wells-Jordan P; Gaba A; Poile C; Baitei EY; Bzura A; Dzialo J; Jama M; Le Quesne J; Bajaj A; Martinson L; Shaw JA; Pritchard C; Kamata T; Kuse N; Brannan L; De Philip Zhang P; Yang H; Griffiths G; Wilson G; Swanton C; Dudbridge F; Hollox EJ; Fennell DA
Nat Commun; 2021 Mar; 12(1):1751. PubMed ID: 33741915
[TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing identifies potential novel therapeutic targets in Chinese HGSOC patients.
Tao J; Sun D; Zhou H; Zhu J; Zhang X; Hou H
Pathol Res Pract; 2022 Oct; 238():154074. PubMed ID: 35988354
[TBL] [Abstract][Full Text] [Related]
15. The Role of Germline Mutations in Thoracic Malignancies: Between Myth and Reality.
Farinea G; Crespi V; Listì A; Righi L; Bironzo P; Merlini A; Malapelle U; Novello S; Scagliotti GV; Passiglia F
J Thorac Oncol; 2023 Sep; 18(9):1146-1164. PubMed ID: 37331604
[TBL] [Abstract][Full Text] [Related]
16. Progression inference for somatic mutations in cancer.
Peterson LE; Kovyrshina T
Heliyon; 2017 Apr; 3(4):e00277. PubMed ID: 28492066
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
18. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.
Guo G; Chmielecki J; Goparaju C; Heguy A; Dolgalev I; Carbone M; Seepo S; Meyerson M; Pass HI
Cancer Res; 2015 Jan; 75(2):264-9. PubMed ID: 25488749
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic mutation profiling in new lung cancer and mesothelioma cell lines.
Lam DC; Luo SY; Deng W; Kwan JSh; Rodriguez-Canales J; Cheung AL; Cheng GH; Lin CH; Wistuba II; Sham PC; Wan TS; Tsao SW
Onco Targets Ther; 2015; 8():195-209. PubMed ID: 25653542
[TBL] [Abstract][Full Text] [Related]
20. What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing.
Wilson MA; Morrissette JJ; McGettigan S; Roth D; Elder D; Schuchter LM; Daber RD
Cancer Genet; 2014 Jun; 207(6):272-5. PubMed ID: 25178945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
